Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker AVIR · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | A Study of GSM-779690T in Healthy Adult Participants NCT07690228 · Healthy Adult Participants, Alzheimer Disease GSM-779690T, Placebo | AVIR Acta Pharmaceuticals | Phase 1 | Recruiting was not yet recruiting | 72 | Nov 2027 | Registry ↗ |
| Oct 29, 2026 | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV NCT06868264 · HEPATITIS C VIRUS CHRONIC INFECTION Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (S… | AVIR Atea Pharmaceuticals, Inc. | Phase 3 | Completed was active, not recruiting | 940 | Jun 18, 2026 | Registry ↗ |
| Oct 28, 2026 | Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Metha… NCT07314346 · Healthy Volunteer Study Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 30 | Jul 23, 2026 | Registry ↗ |
| Jul 31, 2026 | Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Imp… NCT06911320 · Healthy Volunteer Study, Hepatic Impairment Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combinat… | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 28 | Apr 30, 2026 | Registry ↗ |
| Jul 27, 2026 | Study of AT-587 in Healthy Subjects NCT07728487 · Hepatitis E AT-587, Placebo | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Recruiting | 62 | Dec 2026 | Registry ↗ |
| Jun 29, 2026 | C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV NCT07037277 · HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir | AVIR Atea Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 880 | Dec 2026 | Registry ↗ |
| Apr 13, 2026 | Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestre… NCT07272889 · Healthy Volunteer Study Ethinyl Estradioll/Levonorgestrel (EE/LNG), Bemnifosbuvir/R… | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 24 | Feb 17, 2026 | Registry ↗ |
| Jan 7, 2026 | A Clinical Trial to Study Single- and Multiple- Doses of GSM-779690T in Healthy Participants NCT07155980 · Healthy Adult Participants GSM-779690T, Placebo | AVIR Acta Pharmaceuticals | Phase 1 | Withdrawn | 0 | Jul 11, 2026 | Registry ↗ |
| Oct 21, 2025 | A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic H… NCT05904470 · Chronic Hepatitis C Virus, Hepatitis C, Chronic Bemnifosbuvir, Ruzasvir | AVIR Atea Pharmaceuticals, Inc. | Phase 2 | Completed | 275 | Dec 9, 2024 | Registry ↗ |
| Aug 29, 2025 | Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir NCT07007806 · Healthy Volunteer Study Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting… | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 20 | Jun 28, 2025 | Registry ↗ |
| Aug 29, 2025 | Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin NCT06921941 · Healthy Volunteer Study Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR, Rosuv… | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 38 | Jul 2, 2025 | Registry ↗ |
| Jun 13, 2025 | SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19 NCT05629962 · Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2… Bemnifosbuvir (BEM), Placebo | AVIR Atea Pharmaceuticals, Inc. | Phase 3 | Completed | 2,285 | Apr 25, 2024 | Registry ↗ |
| Sep 19, 2024 | Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir NCT06204679 · Healthy Volunteer Study Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting condit… | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 42 | Aug 25, 2024 | Registry ↗ |
| Jul 31, 2024 | Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir NCT06356194 · Healthy Volunteer Study Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-ad… | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 28 | May 30, 2024 | Registry ↗ |
| Jul 31, 2024 | Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function NCT05724693 · Healthy Volunteer, Hepatic Impairment Bemnifosbuvir (BEM) | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 39 | Apr 23, 2024 | Registry ↗ |
| Jul 31, 2024 | Study of AT-527 in Subjects With Normal and Impaired Renal Function NCT05618314 · Healthy Volunteer, Renal Impairment AT-527, AT-527 | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 36 | Jun 15, 2024 | Registry ↗ |
| Mar 5, 2024 | Study of AT-752 in Patients With Dengue Infection NCT05466240 · Dengue Fever AT-752, Placebo | AVIR Atea Pharmaceuticals, Inc. | Phase 2 | Terminated | 21 | Jan 19, 2023 | Registry ↗ |
| Jun 15, 2023 | The Study of Bemnifosbuvir in Healthy Japanese Subjects NCT05905497 · Healthy Volunteer Study Bemnifosbuvir (BEM) | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 14 | May 19, 2023 | Registry ↗ |
| Jun 15, 2023 | Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects NCT05905484 · Healthy Volunteer Study Bemnifosbuvir (BEM), Placebo | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 35 | May 31, 2023 | Registry ↗ |
| Jun 1, 2023 | Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir NCT05731843 · Healthy Volunteer Study Cohort 1 BEM + Ruzasvir, Cohort 2 Ruzasvir + BEM | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 32 | Mar 15, 2023 | Registry ↗ |
| Apr 21, 2023 | Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model NCT05366439 · Dengue AT-752, Placebo Comparator | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Terminated | 5 | Mar 16, 2023 | Registry ↗ |
| Mar 9, 2023 | Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospita… NCT04396106 · COVID-19 AT-527, Placebo | AVIR Atea Pharmaceuticals, Inc. | Phase 2 | Terminated | 83 | Jan 10, 2022 | Registry ↗ |
| Oct 18, 2022 | Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal NCT05256732 · Healthy Volunteer Study AT-527 fasted, Placebo Comparator fasted | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 136 | Aug 23, 2022 | Registry ↗ |
| Oct 17, 2022 | Study of AT-752 in Healthy Subjects NCT04722627 · Dengue AT-752, Placebo | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 65 | Nov 14, 2021 | Registry ↗ |
| Jun 8, 2022 | Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects NCT04309734 · Hepatitis C, Hepatitis C, Chronic AT-777, Placebo | AVIR Atea Pharmaceuticals, Inc. | Phase 1/2 | Withdrawn | 0 | Jun 2022 | Registry ↗ |
| Feb 28, 2022 | Drug-drug Interaction Study of Digoxin and AT-527 (R07496998) NCT05137626 · Healthy Volunteers Study AT-527 + digoxin, AT-527 + digoxin | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 29 | Dec 12, 2021 | Registry ↗ |
| Feb 25, 2022 | Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998) NCT05154123 · Healthy Volunteer Study Drug: AT-527 + rosuvastatin, AT-527 + rosuvastatin | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 29 | Dec 23, 2021 | Registry ↗ |
| Feb 25, 2022 | Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998) NCT05004415 · Healthy Volunteer Study AT-527 (R07496998) | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 6 | Aug 12, 2021 | Registry ↗ |
| Feb 25, 2022 | Bronchopulmonary PK of AT-527 (R07496998) NCT04877769 · Healthy Volunteer Study AT-527 | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 24 | Aug 31, 2021 | Registry ↗ |
| Feb 25, 2022 | Study of AT-527 in Healthy Subjects (R07496998) NCT04711187 · Healthy Volunteer Study AT-527 Formulation 1, Placebo Comparator | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 81 | Sep 15, 2021 | Registry ↗ |
| Aug 2, 2021 | Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998) NCT04849299 · Healthy Volunteer Study AT-527 550 mg + cyclosporine, AT-527 550 mg + cyclosporine | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 24 | May 10, 2021 | Registry ↗ |
| Jul 29, 2021 | Drug-drug Interaction Study of Midazolam and AT-527 (R07496998) NCT04865445 · Healthy Volunteer Study AT-527 550 mg + midazolam, AT-527 550 mg + midazolam | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 24 | May 15, 2021 | Registry ↗ |
| Jul 29, 2021 | Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527 NCT04784000 · Healthy Volunteer Study Period 1: AT-527 550 mg, Period 2: carbamazepine | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 20 | Apr 10, 2021 | Registry ↗ |
| May 4, 2020 | Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection NCT04019717 · Hepatitis C, Hepatitis C, Chronic AT-527, Daclatasvir | AVIR Atea Pharmaceuticals, Inc. | Phase 2 | Completed | 10 | Jan 29, 2020 | Registry ↗ |
| Feb 18, 2020 | Study of AT-527 in Healthy and HCV-Infected Subjects NCT03219957 · Chronic Hepatitis C, Hepatitis C AT-527, Placebo Comparator | AVIR Atea Pharmaceuticals, Inc. | Phase 1 | Completed | 88 | Jun 20, 2018 | Registry ↗ |
35 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:08 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances